|
“More Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic Keratosis” is a continuing medical education program that aims to bridge some of the existing professional practice gaps that primary care clinicians may have regarding common dermatologic problems. This program will educate primary care clinicians about the clinical management of both acne vulgaris and actinic keratosis. Participants will learn about the prevalence and impact of both conditions, as well as practical methods for making the correct diagnosis. A comprehensive overview of the newest and most efficacious treatment options will be discussed, with an additional emphasis on their associated benefits and adverse effects.
Learning Objectives
After completing this activity, the participant will be able to:
- Confidently diagnose patients presenting with the basic dermatologic conditions of acne vulgaris and actinic keratosis
- Identify the most commonly used treatments for acne vulgaris and actinic keratosis
Release Date: February 23, 2009
Expiration Date: February 23, 2010
Medium: Podcast
Acknowledgement of Commercial Support:
This activity was developed from the live Best Practices in Primary Care™ program held in Houston, Texas on June 14, 2008 which was funded by sanofi-aventis US.
Method of Participation:
To receive CME credit for this activity, you need to listen to the program. Upon finishing the podcast, complete the post-test and evaluation, and fill out all required personal information. To receive your CME certificate you will need to pass the post-test with 70% accuracy or better.
Post-test and Evaluation:
After completing this activity, click on the Post-test button at the end of the program. If you receive less than 70% on the post-test, you will be returned to the beginning of the activity to review the presentation again. Upon successful completion of the post-test, you will be asked to fill out a program evaluation form and prompted to print your CME certificate.
Statement of Disclosure and Independence:
It is the policy of Primary Care Network, Inc. to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, Primary Care Network has Conflict of Interest and Disclosure Policies that are designed to ensure that Primary Care Network sponsored educational activities are fair balanced, independent, evidence-based and based on scientific rigor.
Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a Primary Care Network sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
The opinions, ideas, recommendations, and perspectives expressed in the accompanying presentations at this Primary Care Education program are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, Primary Care Education, Advisory Boards and Consultants, or the activity’s commercial supporters.
Planning Committee and Disclosures
Seth Orlow, MD, PhD
Chairman of Dermatology
Professor of Dermatology, Cell Biology, & Pediatrics
New York University School of Medicine
New York, NY
Dr. Orlow is a member of the speaker’s bureau for Ranbaxy Pharmaceuticals Inc. and sanofi-aventis US. He serves on the advisory boards for Barrier Therapeutics, Inc., Graceway Pharmaceuticals, Inc., and Novartis Pharmaceuticals and is also a consultant to Astellas Pharma Inc. and Johnson & Johnson.
Guy Webster, MD, PhD
Clinical Professor of Dermatology
Thomas Jefferson University
Philadelphia, PA
Dr. Webster is a consultant to Allergan, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Johnson & Johnson, Medicis Pharmaceutical Corporation, QLT Inc., Ranbaxy Pharmaceuticals Inc., and Stiefel Laboratories, Inc. He is also a stock shareholder of Endo Pharmaceuticals.
Mary Jo Krey
Senior Project Editor
Haymarket Medical
Montvale, NJ
Ms. Krey has nothing to disclose.
John Puglisi
Editor
Haymarket Medical
Montvale, NJ
Mr. Puglisi has nothing to disclose.
Ana Maria Albino
Program Manager
Haymarket Medical
Montvale, NJ
Ms. Albino has nothing to disclose.
Faculty and Disclosures
Andrew F. Alexis, MD, MPH
Director, Skin of Color Center
St. Luke’s-Roosevelt Hospital
Assistant Clinical Professor of Dermatology
Columbia University College of Physicians and Surgeons
New York, NY
Dr. Alexis is an investigator for Abbott Laboratories. He is a member of the speaker’s bureau for Amgen Inc., CollaGenex Pharmaceuticals Inc., sanofi-aventis, Stiefel Laboratories, Inc., and UCB Pharma. Dr. Alexis serves on advisory boards for Galderma Laboratories and sanofi-aventis, is a consultant to Estee-Lauder, and receives grant support from L’Oreal.
Anthony J. Mancini, MD, FAAP, FAAD
Head, Division of Pediatric Dermatology
Children’s Memorial Hospital
Associate Professor of Pediatrics and Dermatology
Northwestern University’s Feinberg School of Medicine
Chicago, IL
Dr. Mancini is a member of the speaker’s bureau for Astellas Pharma Inc. and Graceway Pharmaceuticals, LLC. He is also a consultant to Medicis Pharmaceutical Corporation, Sciele Pharma, Inc., and SkinMedica, Inc.
Review Committee Disclosure
In accordance with our policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.
Unlabeled Use Declaration:
During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.
 Listen to Podcast
When finished, click here to take the Post-test
Take the post-test to receive your CME certificate
|
